Colospan focuses on developing novel proprietary technology for colorectal surgery
Colospan Ltd. is a clinical stage medical device company, active since 2010. The company is dedicated to meeting the first and foremost challenge in colorectal surgery by addressing the profound clinical and economic pains associated with anastomotic leaks. Colospan focuses on developing a safe, effective alternative for the ostomy pouch, to improve medical procedures, reduce health risks and upgrade patients’ wellbeing. Bringing together clinical, technical and marketing expertise since its inception, its team consists of seasoned professionals as well as leading colorectal surgeons on a global scale. It also boasts a distinguished scientific advisory team comprising KOL physicians from Europe and the United States specializing in the colorectal field.
Colospan has attained the CE mark for gastro-intestinal devices as well as ISO 13485 certification, and is in the process of attaining FDA clearance. With strong IP, Colospan has registered patents in the United States, China and Japan. It has completed an animal study, as well as a prospective multi-center trial with 60 patients, designed to evaluate safety, tolerability and performance of the CG-100 device. Colospan enjoys solid financial backing from leading VCs from Israel, Europe and China, including VLVJ, Anatomy, Docor, Virtus Inspire and the Alfred Mann Institute of Technology, part of the Technion Institute of Technology.
Founder & CEO
VP Clinical Affairs
VP R&D and Operations
VP Regulatory Affairs
Sales & Marketing Manager
Colospan Ltd has received funding from the European Union’s Horizon 2020 research and innovation programme
under grant agreement No:762833